Fulgent Therapeutics LLC
El Monte, CA Doing business as Fulgent Diagnostics Part of Fulgent Genetics, Inc.
- UEI
- JVZDRESJLD82
- CAGE
- 7BRL2
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Expired
Company facts
- FY2025 rankings
-
Its parent company, Fulgent Genetics, Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
El Monte, CA
Y9JMAEN8GRK6
-
- El Monte, CA Y9JMAEN8GRK6
- El Monte, CA UC4DKMPCBR84
-
-
Parent
El Monte, CA
Y9JMAEN8GRK6
- SAM.gov registration date
- Physical address
- 4399 Santa Anita Ave, El Monte, CA 91731, USA
- Website
- fulgentgenetics.com
- Founded
- 2011
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$1,703,261 |
| FY2025 | $7,338,171 |
| FY2024 | $4,777,912 |
| FY2023 | $2,280,493 |
Contract vehicles
Expired vehicles (1)
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The General Hospital Corporation | U2CCA271871 | $126,156 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Baylor Miraca Genetics Laboratories LLC | Houston, TX | 621511 Medical Laboratories |
| Fulgent Genetics, Inc. | El Monte, CA | 621511 Medical Laboratories |
| Konica Minolta Healthcare Americas, Inc., Wayne, NJ | Aliso Viejo, CA | 621511 Medical Laboratories |
| Prevention Genetics | Marshfield, WI | 621511 Medical Laboratories |
| Invitae Corporation | — | 621511 Medical Laboratories |
About the company
Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, is a subsidiary of Fulgent Genetics, Inc. that delivers reference laboratory testing and genomic sequencing services to federal healthcare agencies as a prime contractor on 23 of 24 recent awards. The company operates under open competition with no set-aside designations across medical laboratory testing and genetic diagnostic work, drawing $171.4 million in combined potential value from 24 federal awards spanning contract vehicles, purchase orders, blanket purchase agreements, and a single grant sub-award role.
The company is structured as a limited liability partnership for-profit organization headquartered in El Monte, California, with primary NAICS coding in Medical Laboratories (621511) and reference laboratory testing under PSC Q301. Fulgent Therapeutics operates predominantly as a self-performing prime — across SCI-reportable federal service contracts captured from FY2022 through FY2025, the vendor invoiced $19.9 million with zero average subcontractor-hours share, indicating all work is delivered by the vendor's own personnel. SCI-reported FTE trajectory shows 1.2 FTEs in FY2022, declining to 0.9 FTEs in FY2023, then growing through FY2024 (3.2 FTEs) and FY2025 (13.4 FTEs), reflecting expansion in deliverable scope. Government-paid hourly rates on SCI-reportable contracts run median $199.88/hr, with 90th-percentile senior labor pricing through $3,407.96/hr.
Customer concentration is acute and anchored to Veterans Affairs. The Department of Veterans Affairs Strategic Acquisition Center Frederick dominates both volume and potential value — 5 awards worth $119.5 million combined potential value. VA's Veterans Integrated Service Network 19 contributes 4 awards worth $246 thousand; the Department of the Army Medical Command holds 3 awards worth $2.4 million; and the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh holds 1 award worth $40.5 million. The top five customers account for 98% of combined potential value across 14 distinct agencies served.
Fulgent Therapeutics' primary vehicle position is the Germline PGx Services indefinite delivery contract issued by VA Strategic Acquisition Center Frederick on September 30, 2024, with a $99.032 million ceiling running through September 29, 2029. Three delivery orders have been placed under this IDIQ: a $2.949 million supplemental agreement for germline pharmacogenomic molecular testing awarded September 30, 2024; a $6.573 million Year 2 within-scope modification supporting the Veterans Health Administration National Oncology Program awarded September 30, 2025; and a $6.573 million germline PGX molecular testing delivery order awarded September 30, 2026. The vendor also holds a $500,000 Blanket Purchase Agreement with the Defense Health Agency awarded September 8, 2025, for genetic testing services at Tripler Army Medical Center in Hawaii, and a Medical Laboratory Testing and Analysis Services vehicle carrying a $3.2 million order. Representative non-IDC work includes a $4.339 million purchase order from VA Strategic Acquisition Center Frederick awarded September 27, 2022, for germline genetic testing supporting the National Oncology Program, and a $1.003 million definitive contract with VA Veterans Integrated Service Network 17 for genetics testing awarded October 1, 2024.
Activity has been episodic. Awards numbered 3 in 2022, dropped to 1 in 2023, returned to 3 in 2024 and 2025, and 1 in 2026 (year-to-date). Combined dollars obligated across all awards reach $58 million (34% of combined potential value), reflecting that many task orders under the large VA IDIQ remain partially unspent. Within the next twenty-four months, one award carrying $6.6 million in combined potential value reaches ultimate completion, creating a single recompete exposure point.
Fulgent Therapeutics operates as a sub-recipient on one federal grant awarded December 29, 2025, through The General Hospital Corporation as prime grantee. Under this National Institute of Child Health and Human Development grant, Fulgent provides design and oversight of plasma and serum protein assays on the Olink platform and conducts methylation assay work at its CLIA/CAP certified laboratory, analyzing de-identified biospecimens from the EDRN Uterine Lavage Study and delivering statistical analysis and quality-control metrics to the MGH principal investigator through year 5 of the project. The grant scope includes collaboration with MGH personnel on assay standardization and biomarker characterization.
Fulgent Therapeutics' federal capability portfolio centers on next-generation sequencing, germline genetic testing across oncology and medical genetics specialties, pharmacogenomic molecular testing, clinical genetic testing, anatomic pathology laboratory services, and result interpretation. Work is performed at multiple locations including Frederick, Maryland (primary VA IDC performance site), El Monte, California (headquarters and laboratory), Temple City, California, Tucson, Arizona, and Hawaii. All federal contracts are firm fixed price with no subcontractor engagement reported.
Quick answers
Is Fulgent Therapeutics LLC registered in SAM.gov?
Fulgent Therapeutics LLC's SAM.gov registration expired on June 18, 2026.
Which contract vehicles does Fulgent Therapeutics LLC hold?
Fulgent Therapeutics LLC holds a place on 2 federal contract vehicles, including Germline PGx Services.
How much has Fulgent Therapeutics LLC received in federal contracts?
Federal contracts obligated $7,338,171 to Fulgent Therapeutics LLC in fiscal year 2025 and $12,693,314 in fiscal years 2023 through 2027.
How does Fulgent Therapeutics LLC rank among federal contractors?
Fulgent Therapeutics LLC's parent company, Fulgent Genetics, Inc., ranked #9 in NAICS 621511, #11 in NAICS 6215 and #11 in PSC Q3 in FY2025.
What is Fulgent Therapeutics LLC's most recent federal award?
Fulgent Therapeutics LLC's most recent federal contract award is Germline PGX molecular testing (36C10X26N0165), from VA Strategic Acquisition Center Frederick, on September 30, 2026.
On GovTribe
See Fulgent Therapeutics LLC's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors